Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
FR0012333284
Mon, 24.05.2021
ABIVAX
Abivax suspends trading of its shares until the publication of ABX464 Phase 2b results in ulcerative colitis
PARIS, France, May 24, 2021 - 08:45 am (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX) (the "Company"), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory [ … ]
Fri, 30.04.2021
ABIVAX
Abivax publishes Universal Registration Document 2021 "Document d'Enregistrement Universel"
PARIS, France, April 30, 2021 - 06:00 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, [ … ]
Mon, 19.04.2021
ABIVAX
Abivax Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcerative Colitis
The Webinar takes place on Tuesday, April 20, 2021 at 7:30am EDT (1:30pm CEST)
PARIS, France, April 19, 2021 - 6:00 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that mod [ … ]
Wed, 14.04.2021
ABIVAX
Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis
16-weeks induction treatment with ABX464 in phase 2b clinical study in ulcerative colitis completed for the 254 patients enrolled, with reduction of Total Mayo Score after 8 weeks as primary endpoint
Top-line data of induction phase to bec [ … ]
Wed, 31.03.2021
ABIVAX
Abivax reports 2020 financial results and operations update
Recruitment completed in ABX464 phase 2b ulcerative colitis and phase 2a rheumatoid arthritis studies; top-line results for both studies will become available in Q2 2021
Excellent short- and long-term efficacy and safety data for 50 mg once-daily oral ABX464 in ulcerative colitis phase 2 [ … ]
Tue, 05.01.2021
ABIVAX
Abivax Publishes Review in Drug Discovery Today on Mechanism of Action and Transformative Potential of ABX464 as Therapy for Inflammatory Diseases
Scientific review summarizes the molecular events leading to potent anti-inflammatory effects of lead molecule ABX464, centered around the specific upregulation of microRNA-124 (miR-124)
Scientific dat [ … ]
Tue, 22.12.2020
ABIVAX
Abivax's Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government's Clinical Trial Council
Research National Priority has priority for patient enrollment in clinical trials for an accelerated review and approval process with the French regulatory authorities
Effective Covid-19 treatments very much [ … ]
Mon, 21.12.2020
ABIVAX
Abivax to present at the 39th Annual J.P. Morgan Healthcare Conference ahead of major clinical milestones
PARIS, December 21, 2020 - 6:30 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, to [ … ]
Wed, 09.12.2020
ABIVAX
Abivax establishes clinical, regulatory and manufacturing framework for ABX464 phase 3 program and potential commercialization in 2021
Pivotal ABX464 clinical trials ongoing or planned for three indications: Ulcerative colitis, Crohn's disease and Covid-19
Four phase 1 studies are being initiated to generate complementary data to support the late [ … ]
Thu, 03.12.2020
ABIVAX
Abivax 2021 Financial Communication Calendar
PARIS, FRANCE, December 3, 2020 - 6:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today publishes its 2021 financial communication calenda [ … ]